Initial Registration Statement (Form S-1)

As filed with the Securities and Exchange Commission on September 30, 2025

Registration No. 333-[__]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM S-1

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

FUTURE FINTECH GROUP INC.

(Exact name of registrant as specified in its charter)

Florida		6159		98-022013
(State or Other Jurisdiction of		(Primary Standard Industrial		(I.R.S. Employer
Incorporation or Organization)		Classification Code Number)		Identification Number)

02B-03A, 23/F, Sino Plaza, 255-257

Gloucester Road, Causeway Bay, Hong Kong

888-622-1218

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Mr. Hu Li

Chief Executive Officer

Americas Tower, 1177 Avenue of the Americas, Suite 5100

New York, NY 10036

888-622-1218

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Laura Anthony, Esq.

Craig D. Linder, Esq.

Anthony, Linder & Cacomanolis, PLLC

1700 Palm Beach Lakes Blvd, Suite 820

West Palm Beach, Florida 33401

(561) 514-0936

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-Accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the commission, acting pursuant to section 8(a) may determine.

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS

SUBJECT TO COMPLETION

DATED SEPTEMBER 30, 2025

Future Fintech Group Inc.

Resale of up to 20,105,000 Shares of Common Stock

This prospectus relates to the resale by the selling stockholders named in this prospectus of:

(i)

up to 10,000,000 shares of common stock potentially issuable to Avondale Capital, LLC ("Avondale") in satisfaction of pre-paid purchase balances outstanding from time to time (the "Purchase Shares") under the Securities Purchase Agreement dated as of July 28, 2025, by and between us and Avondale (the "Pre-Paid SPA") subject to such limitation as may be required pursuant to a beneficial ownership limitation equal to 9.99% of the common stock outstanding from time to time. See the section titled "Prospectus Summary - Pre-Paid Securities Purchase Agreement" for a description of the Pre-Paid SPA;

(ii)

60,000 shares of common stock issued to Avondale as a commitment fee (the "Commitment Shares") pursuant to the Pre-Paid SPA;

(iii)

1,445,000 shares of common stock issued to Avondale as pre-delivery shares (the "Pre-Delivery Shares") pursuant to the Pre-Paid SPA;

(iv)

6,000,000 shares of common stock issued pursuant to Securities Purchase Agreements, dated July 28, 2025, with six individual investors (each, a "Purchaser" and collectively, the "Purchasers") (the "Equity SPA"). See the section titled "Prospectus Summary - Offshore Equity Financing" for a description of the Equity Spa; and

(v)

up to an aggregate of 2,600,000 shares of our common stock issuable to FT Global Capital, Inc. ("FT Global") or its designee pursuant to the Settlement and Forbearance Agreement issuable upon their exercise of FT Global's Series A Right to receive 650,000 shares of common stock (after a six month lock-up) and Series B Right to receive 650,000 shares of common stock (after a 12-month lock up), and including a potential 1,300,000 shares of common stock, to the extent that the Company will be required to true-up the shares due to FT Global pursuant to the Settlement Agreement, as described in "Prospectus Summary -Settlement Agreement".

Avondale, the Purchasers, and FT Global, may be collectively referred to herein as the "Selling Stockholders."

Under the Pre-Paid SPA, we may issue and sell one or more pre-paid purchases (each, a "Pre-Paid Purchase"), in the aggregate purchase amount of up to $10,000,000. Upon the terms and subject to the conditions of each Pre-Paid Purchase, Avondale, at its sole discretion, has the right, but not the obligation, to purchase common stock from us, and we will issue to Avondale, common stock in satisfaction of all or a portion of the outstanding balance of such Pre-Paid Purchase, but not exceeding the outstanding balance of such Pre-Paid Purchase (the "Purchase Shares"). Any delivery of the 10,000,000 Purchase Shares registered for resale pursuant to the registration statement of which this prospectus is a part will reduce the outstanding balance of any Pre-Paid Purchase at a rate that will depend upon the timing of a delivery request by Avondale and will fluctuate based on the trading price of our common stock. The number of common stock that may actually be acquired by Avondale pursuant to the Pre-Paid SPA is not currently known and is subject to satisfaction of certain conditions and other limitations, including the limitations specified above. With respect to the Purchase Shares, Avondale is an underwriter within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the "Securities Act").

The shares of our common stock may be sold publicly or through private transactions by the Selling Stockholders at prevailing market prices or at negotiated prices at the times of sale. The shares of common stock may be offered by the Selling Stockholders to or through underwriters, dealers or other agents, directly to investors or through any other manner permitted by law, on a continued or delayed basis. The Selling Stockholders are deemed underwriters within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended. We provide more information about how the Selling Stockholders may sell or otherwise dispose of the shares of common stock in the section entitled "Plan of Distribution" beginning on page 22 of this prospectus.

We are not selling any shares of common stock in this offering, and we will not receive any proceeds from the sale of shares by the Selling Stockholders. However, we may receive up to an additional $10,000,000 in aggregate gross proceeds from Avondale under the Pre-Paid SPA. See "Plan of Distribution" and "Selling Securityholders." The registration of the securities covered by this prospectus does not necessarily mean that any of these securities will be offered or sold by the Selling Stockholders. The timing and amount of any sale is within the Selling Stockholders' sole discretion, subject to certain restrictions. To the extent that the Selling Stockholders resell any securities, the Selling Stockholders may be required to provide you with this prospectus identifying and containing specific information about the Selling Stockholders and the terms of the securities being offered.

We are a "smaller reporting company" as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and are subject to reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is smaller reporting company.

Our common stock is listed on the Nasdaq Capital Market under the symbol "FTFT". On September 29, 2025, the closing price of our common stock was $2.17.

We will bear all costs, expenses and fees in connection with the registration of the shares of common stock. The Selling Stockholders will bear all commissions and discounts, if any, attributable to their sales of the shares of common stock.

Our business and investment in our common stock involve significant risks. These risks are described in the section titled "Risk Factors" beginning on page 12 of this prospectus.

Neither the Securities and Exchange Commission ("SEC") nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is _________, 2025.

TABLE OF CONTENTS

	Page
ABOUT THIS PROSPECTUS	ii
PROSPECTUS SUMMARY	1
THE OFFERING	10
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	11
RISK FACTORS	12
USE OF PROCEEDS	16
DETERMINATION OF OFFERING PRICE	16
MARKET PRICE AND DIVIDEND POLICY	16
DESCRIPTION OF SECURITIES	18
SELLING STOCKHOLDERS	20
PLAN OF DISTRIBUTION	22
MATERIAL TAX CONSIDERATIONS	25
LEGAL MATTERS	29
EXPERTS	29
WHERE YOU CAN FIND MORE INFORMATION	29
INFORMATION INCORPORATED BY REFERENCE	30

ABOUT THIS PROSPECTUS

The registration statement of which this prospectus forms a part that we have filed with the Securities and Exchange Commission ("SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC before making your investment decision.

Unless the context otherwise requires, references in this prospectus to "FTFT," "the Company," "we," "us" and "our" refer to Future Fintech Group Inc. and our subsidiaries. Solely for convenience, trademarks and tradenames referred to in this prospectus may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.

RISK FACTORS

Investing in our securities involves a high degree of risk. You should consider carefully the additional risks described below, together with all of the other information included or incorporated by reference in this prospectus, including the risks and uncertainties discussed under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, before deciding whether to purchase our securities in this offering. All of these risk factors are incorporated herein in their entirety. The risks described below and incorporated by reference are material risks currently known, expected or reasonably foreseeable by us. However, the risks described below or that we incorporate by reference are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects or financial condition. If any of these risks actually materialize, our business, prospects, financial condition, and results of operations could be seriously harmed. This could cause the trading price of our common stock and the value of the warrants to decline, resulting in a loss of all or part of your investment.

Risks Related to the Transactions under the Pre-Paid SPA

It is not possible to predict the actual number of shares of common stock, if any, we will sell under the Pre-Paid SPA to Avondale, or the actual gross proceeds resulting from the Pre-Paid SPA.

Pursuant to the Pre-Paid SPA, Avondale has committed to provide up to $10,000,000 of funding through one or more pre-paid purchases of our common stock, subject to certain limitations and conditions set forth in the Pre-Paid SPA. The shares of our common stock that may be issued under the Pre-Paid SPA may be delivered to Avondale upon its election to convert (via a "Purchase Notice") outstanding balances under the Pre-Paid SPA into common stock.

We do not control the timing or amount of shares Avondale may elect to receive in satisfaction of outstanding balances under the Pre-Paid SPA. The issuance of our common stock to Avondale under the Pre-Paid SPA will depend upon market conditions and other factors, including Avondale's decision to submit Purchase Notices. We may ultimately issue to Avondale all, some, or none of the shares of our common stock available under the Pre-Paid SPA. Depending on market liquidity at the time, resales of those shares by Avondale may cause the public trading price of our common stock to decrease.

Because the purchase price per share to be deemed paid by Avondale for the shares of our common stock issued under the Pre-Paid SPA will fluctuate based on the market prices of our common stock during the term of the Pre-Paid SPA, it is not possible for us to predict, as of the date of this prospectus, the number of shares of our common stock that we will issue to Avondale under the Pre-Paid SPA, the deemed purchase price per share, or the aggregate gross proceeds that we will receive.

Our inability to access a portion or the full amount available under the Pre-Paid SPA, in the absence of any other financing sources, could have a material adverse effect on our business.

Although the Pre-Paid SPA provides for funding of up to $10,000,000, our ability to access the full amount is subject to numerous conditions, including trading volume requirements, share reserve obligations, market capitalization thresholds, and the absence of defaults. If we cannot satisfy these conditions, we may not be able to receive all of the funding available.

The sale and issuance of our common stock to the Avondale will cause dilution to our existing stockholders, and the sale of the shares of our common stock acquired by the Avondale or the perception that such sales may occur, could cause the price of our common stock to fall.

The purchase price of our common stock issued to Avondale under the Pre-Paid SPA will fluctuate based on the price of the shares of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to fall. If and when we do sell shares to Avondale, after Avondale has acquired the shares, Avondale may resell all, some, or none of those shares at any time or from time to time in its discretion. Therefore, sales to Avondale by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Avondale, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

Investors who buy our common stock from Avondale at different times will likely pay different prices.

Pursuant to the Pre-Paid SPA, Avondale will have discretion to vary the timing, prices, and numbers of shares of common stock it wishes to purchase, following their pre-payment for such shares. If and when we do elect to direct Avondale to pre-purchase shares of our common stock pursuant to the Pre-Paid SPA, and after Avondale has acquired such shares, Avondale may resell all, some or none of such shares at any time or from time to time in its discretion and at different prices. As a result, investors who purchase shares from Avondale in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from Avondale in this offering as a result of future sales made by us to Avondale at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to Avondale under the Pre-Paid SPA, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with Avondale may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales.

Avondale has acquired and may acquire our common stock at a price below the current trading price of the common stock through discounted pre-paid purchase arrangements, and may experience a positive rate of return based on the current trading price. Future investors in the Company may not experience a similar rate of return, and additionally this could cause the price of our common stock to decline.

The purchase price of our common stock issued to Avondale under the Pre-Paid SPA is derived from the market price of our common stock on Nasdaq, subject to a floor price. Shares to be sold to Avondale pursuant to the Pre-Paid SPA will be deemed to have been issued at a discounted price. Additionally, the Commitment Shares were issued to Avondale for non-cash consideration. These factors may create an economic incentive for Avondale to sell the shares it receives immediately after the effectiveness of the registration statement to which this prospectus is a part, or after receipt of the Purchase Shares, which could cause the price of our common stock to decrease. As a result, other investors may experience dilution or decline in the value of their holdings, and future investors may face a less favorable investment opportunity.

If we fail to comply with certain covenants or conditions under the Pre-Paid SPA, including maintaining our Nasdaq listing or timely delivering shares, the outstanding balance may become immediately due and payable in cash at a premium, and default interest of up to 18% per annum may apply.

Each Pre-Paid Purchase accrues interest at an annual rate of 8% and includes an original issue discount of 8%. If the registration statement of which this prospectus is a part, is not declared effective within 90 calendar days of the effective date of the initial Pre-Paid Purchase (July 28, 2025), the outstanding balance of the Pre-Paid Purchase will automatically increase by 1% on such 90th day and by an additional 1% for each subsequent 30 day period that the registration statement remains ineffective, up to a maximum increase of 4%. The Pre-Paid SPA also provides that Avondale may not engage in short sales of our common stock during the term of the facility, and, so long as no event of default has occurred, Avondale may not sell more than 15% of the weekly trading volume of our common stock in any given calendar week. If we fail to comply with certain covenants or conditions under the Pre-Paid SPA, including maintaining our Nasdaq listing or timely delivering shares, the outstanding balance may become immediately due and payable in cash at a premium, and default interest of up to 18% per annum may apply.

Our management team will have broad discretion over the use of the net proceeds from funds received under the Pre-Paid SPA, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully.

Our management team will have broad discretion as to the use of the net proceeds from funds received under the Pre-Paid SPA, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management team with regard to the use of those net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows.

Risks Related to the Transactions under the Settlement Agreement

If we fail to make required payments or issue securities when due, and do not cure such breach within the limited cure period, FT Global may declare us in default and be entitled to immediately enforce outstanding judgments against us, which could result in the seizure of our assets and a material adverse effect on our financial condition.

On June 17, 2025, we entered into the Settlement Agreement with FT Global. Under the Settlement Agreement, we are required to make a series of cash payments totaling approximately $4.0 million, issue shares of our common stock, and grant rights to acquire additional shares. If we fail to make required payments or issue securities when due, and do not cure such breach within the limited cure period, FT Global may declare us in default. In that event, FT Global would be entitled to immediately enforce outstanding judgments against us, which could result in the seizure of our assets and a material adverse effect on our financial condition.

The requirement that 25% of the cash proceeds we receive from any financings outside of Mainland China must be applied toward our obligations to FT Global may limit the net proceeds available to fund our operations or growth initiatives and could restrict our ability to raise and use capital efficiently.

Under the Settlement Agreement, 25% of the cash proceeds we receive from any financings outside of Mainland China must be applied toward our obligations to FT Global. This requirement may limit the net proceeds available to fund our operations or growth initiatives and could restrict our ability to raise and use capital efficiently.

The sale and issuance of our common stock to FT Global will cause dilution to our existing stockholders, and the sale of the shares of our common stock acquired by FT Global or the perception that such sales may occur, could cause the price of our common stock to fall.

The Settlement Agreement grants FT Global rights to acquire up to an aggregate of 1,300,000 additional shares. We may also be required to issue additional 1,300,000 shares as "true-up" payments if our stock trades below $1.00 at the time of exercise of such rights. These issuances will result in dilution to our existing stockholders and could cause the trading price of our common stock to decline.

If the market price of our common stock falls below $1.00 at the time FT Global exercises its rights, we will be required to make additional "true-up" payments to FT Global in cash or, if permitted, in freely tradable common stock. This could require us to issue additional shares at prices significantly below market value or to make material cash payments, either of which could adversely affect our financial condition and the market price of our stock.

Risks Related to the Transactions under the Equity SPA

If the SEC or a court were to determine that the issuance under the Equity SPA failed to satisfy Regulation S, the shares could be subject to rescission claims, restrictions on transfer, or enforcement actions, any of which could adversely affect holders.

We issued the shares pursuant to the Equity SPA to non-U.S. purchasers in reliance on the registration exemption provided by Regulation S. The Equity SPA represents that each purchaser is a "non-U.S. person," that the offer and sale occurred outside the United States, and that on-sales to U.S. persons are restricted during a one-year distribution compliance period (subject to registration or an available exemption). If the SEC or a court were to determine that the issuance failed to satisfy Regulation S, the shares could be subject to rescission claims, restrictions on transfer, or enforcement actions, any of which could adversely affect holders.

Risks Related to this Offering and our Common Stock

These resales will increase the number of shares available for public trading, which could create downward pressure on the trading price of our common stock.

The Selling Stockholders may resell the shares of our common stock in the open market or in privately negotiated transactions at any time. Such sales, or the perception that they may occur, could depress the trading price of our common stock. These resales will increase the number of shares available for public trading, which could create downward pressure on the trading price of our common stock.

Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our common stock.

Our shares of common stock are currently listed on Nasdaq. If we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, such as the corporate governance requirements, minimum bid price requirement or the minimum stockholders' equity requirement, Nasdaq may take steps to delist our common stock. Any delisting would likely have a negative effect on the price of our common stock and would impair stockholders' ability to sell or purchase their common stock when they wish to do so.

On May 13, 2024, we received written notice (the "Bid Price Notice") from the Nasdaq Staff indicating that we were not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") for continued listing on the Nasdaq Capital Market. The notification of noncompliance had no immediate effect on the listing or trading of our common stock on the Nasdaq Capital Market under the symbol "FTFT.".

The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, and we did not meet this requirement. The Bid Price Notice indicated that the Company will be provided 180 calendar days, in which to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq Staff will provide the Company with written confirmation of compliance and the matter will be closed.

On November 12, 2024, we received written notification from the Nasdaq Staff that we were granted an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement. Nasdaq's determination was based on our having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for listing on Nasdaq, with the exception of the Minimum Bid Price Requirement, and our written notice to Nasdaq of our intention to cure the deficiency by effective a reverse stock split.

On April 1, 2025, we effectuated a 1-for-10 reverse stock split of our authorized shares of common stock from 60,000,000 shares to 6,000,000 shares, accompanied by a corresponding decrease in our issued and outstanding shares of common stock. The 2025 Reverse Stock Split and Amendment were authorized and approved by our Board without shareholders' approval, pursuant to 607.10025 of the Florida Business Corporation Act ("FBCA") of the State of Florida. The 2025 Reverse Stock Split was primarily effectuated to comply with Nasdaq Marketplace Rule 5550(a)(2) related to the Minimum Bid Price Requirement.

On April 28, 2025, we received a written notification from the Nasdaq Staff indicating that we regained compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market and that the matter is now closed.

There can be no assurance that we will be able to maintain our compliance with the Minimum Bid Price Requirement. In addition, we cannot assure you our securities will meet the continued listing requirements to be listed on Nasdaq in the future. If Nasdaq delists our common stock from trading on its exchange, we could face significant material adverse consequences including:

●

a limited availability of market quotations for our securities;

●

a determination that our common stock is a "penny stock" which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;

●

a limited amount of news and analyst coverage for our company; and

●

a decreased ability to issue additional securities or obtain additional financing in the future.

If we fail to maintain compliance with all applicable continued listing requirements for the Nasdaq Capital Market and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock, our ability to obtain financing to repay debt and fund our operations.

USE OF PROCEEDS

We are not selling any shares of common stock in this offering, and we will not receive any proceeds from the sale of shares by the Selling Stockholder. However, we may receive up to an additional $10,000,000 in aggregate gross proceeds from Avondale under the Pre-Paid SPA which we plan to use towards the cash settlement payment of $4,000,000 due to FT Global pursuant to the Settlement Agreement, for general working capital, and to fund strategic growth initiatives. Our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from the Pre-Paid SPA.

The Selling Stockholders will pay any underwriting fees, discounts, selling commissions, stock transfer taxes and certain legal expenses incurred by such Selling Stockholders, as applicable, in disposing of their securities, and we will bear all other costs, fees and expenses incurred in effecting the registration of the securities covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accountants.

DETERMINATION OF OFFERING PRICE

We cannot currently determine the price or prices at which our common stock may be sold by the Selling Stockholders under this prospectus. These sales may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

MARKET PRICE AND DIVIDEND POLICY

Our common stock is listed on the Nasdaq Capital Market under the symbol "FTFT." On September 29, 2025, the last reported sale price of our common stock was $2.17 per share. As of the date of this prospectus, 20,153,311 shares of common stock were issued and outstanding.

Holders of Record

As of September 30, 2025, we had approximately 202 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, this number is not indicative of the total number of stockholders represented by these stockholders of record.

Dividends

We have never declared or paid any cash dividends on our common stock. The payment of dividends is at the discretion of the Board and is contingent on our revenues and earnings, capital requirements, financial condition and the ability of our operating subsidiaries to obtain governmental approval to send funds out of the PRC. We currently intend to retain all earnings, if any, for use in business operations. Accordingly, we do not anticipate declaring any dividends in the near future.

Recent Sales of Unregistered Securities

In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.

On December 27, 2023, we entered into a Securities Purchase Agreement with Streeterville Capital, LLC, a Utah limited liability company, pursuant to which we sold and issued to the purchaser a Convertible Promissory Note (the "Note") in the principal amount of $1,100,000. The Purchaser purchased the Note with an original issue discount of $80,000, and we agreed to pay to the Purchaser $20,000 for fees and costs incurred by Purchaser in connection with the agreement.

On January 5, 2024, we entered into a Securities Purchase Agreement with certain purchasers, pursuant to which we agreed to sell to such in a private placement 2,150,536 shares (the "Shares") of common stock, at a purchase price of $1.20 per share for an aggregate price of $2,580,644. The private placement transaction was completed pursuant to the exemption from registration provided by Regulation S promulgated under the Securities Act of 1933, as amended.

On January 7, 2025, the holder of outstanding convertible note of the Company ("Note") elected to redeem a portion of the Note in 428,816 shares of common stock for an amount of $100,000 with a price of $0.2332 per share. On January 24, 2025, the same holder elected to redeem a portion of the Note in 183,230 shares of common stock for an amount $40,658 at a price of $0.2219 per share. The share numbers and prices are pre- reverse split effected on April 1, 2025.

On June 24, 2025, the United States District Court for the Southern District of New York entered an Order Approving Issuance (the "Section 3(a)(10) Order") pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended (the "Securities Act"), in the matter of FT Global Capital, Inc. v. Future FinTech Group Inc., Case No. 1:24-mc-00257-AKH. The Section 3(a)(10) Order ordered that the issuance and/or transfer of Settlement Shares (as defined below) to FT Global or its designees(s), pursuant to the Settlement Agreement, was approved as fair within the meaning of Section 3(a)(10) of the Securities Act, and the Settlement Shares are exempt from registration with the SEC and shall be issued without any restrictive legends. The Settlement Shares are as follows: (i) 340,000 shares of the Company's common stock to FT Global; (ii) 60,000 shares of the Company's common stock to Olshan Frome Wolosky LLP; (iii) 650,000 shares of the Company's common stock underlying a "Series A Right" for FT Global or its designees(s) to receive 650,000 shares of common stock, exercisable no earlier than six months after June 17, 2025; and (iv) 650,000 shares of common stock underlying a "Series B Right" for FT Global or its designees(s) to receive 650,000 shares of common stock, exercisable no earlier than 12 months after June 17, 2025.

On July 24, 2025, we entered into a securities purchase agreement (the "Equity SPA") with certain institutional and individual investors, pursuant to which we agreed to issue and sell, and the Purchasers agreed to purchase, up to an aggregate of 15,000,000 shares of common stock at a purchase price of $2.00 per share. The initial closing was capped at no more than 19.9% of our outstanding Common Stock as of the closing date and with the issuance of the remaining shares of Common Stock pursuant to the Equity SPA subject to shareholder approval, which was approved at a special meeting of stockholders on September 2, 2025.

On July 28, 2025, we entered into a Pre-Paid Securities Purchase Agreement (the "Pre-Paid SPA") with Avondale Capital, LLC, a Utah limited liability company ("Avondale") up to $10,000,000 worth of shares of common stock. On September 16, 2025, we issued the 60,000 shares as Commitment Shares to Avondale as a fee pursuant to the Pre-Paid SPA. On September 24, 2025, we issued 1,445,000 Pre-Delivery Shares to Avondale in connection with the Pre-Paid SPA.

Unless otherwise noted, the foregoing shares were issued to an accredited investor without registration under the Securities Act of 1933, as amended (the "Securities Act"), based upon exemptions from registration provided under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The issuances did not involve any public offering.

DESCRIPTION OF SECURITIES

The following description of the capital stock is based upon our Third Amended and Restated Articles of Incorporation ("Articles of Incorporation"), our Amended and Restated Bylaws ("Bylaws") and applicable provisions of law, in each case as currently in effect. This discussion does not purport to be complete and is qualified in its entirety by reference to our Articles of Incorporation and Bylaws, copies of which have been filed with the SEC.

Authorized Capital Stock

We are authorized to issue 600,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.

As of September 30, 2025, there were 20,153,311 shares of common stock issued and outstanding and no shares of our preferred stock issued outstanding. As of such date, there were approximately 202 holders of record of our common stock. Our common stock is currently traded on the Nasdaq Capital Market under the symbol "FTFT".

Common Stock

Holders of shares of our common stock are entitled to one vote for each share on all matters to be voted on by the shareholders. Except if a greater plurality is required by the express requirements of law or our Articles of Incorporation, the affirmative vote of a majority of the shares of voting stock represented at a meeting of shareholders at which there shall be a quorum present shall be required to authorize all matters to be voted upon by our shareholders. According to our charter documents, holders of our common stock do not have preemptive rights and are not entitled to cumulative voting rights. There are no conversion or redemption rights or sinking funds provided for our shareholders. Shares of our common stock share ratably in dividends, if any, as may be declared from time to time by the board of directors in its discretion from funds legally available for distribution as dividends. In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled to share pro rata all assets remaining after payment in full of all liabilities. All of the outstanding shares of our common stock are fully paid and non-assessable.

Preferred Stock

Our Articles of Incorporation authorize the Board to issue up to 10,000,000 shares of preferred stock in one or more series, to determine the designations and/ the powers, preferences and rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. The Board could, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock and which could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority of our outstanding voting stock.

Rights

Under the terms of the Settlement Agreement, we agreed to issue (i) rights entitling FT Global to receive 650,000 shares of our common stock underlying a "Series A Right" for FT Global or its designees(s) to receive 650,000 shares of common stock in lieu of a cash settlement payment of $702,000, exercisable no earlier than six months after June 17, 2025; and (iv) rights entitling FT Global to receive 650,000 shares of our common stock underlying a "Series B Right" (the Series A Right and Series B Right, collectively referred to as the "Rights") for FT Global or its designees(s) to receive 650,000 shares of common stock in lieu of a second cash settlement payment of $702,000, exercisable no earlier than 12 months after June 17, 2025 (collectively (i) through (ii) referred to as the "Rights Shares"). If on any exercise date of the Rights the closing bid price of our common stock is less than $1.00, we will be required to make additional "true-up" payments in cash or, if permitted, in freely tradable common stock, equal to the price difference multiplied by the number of shares issued upon exercise of the Rights. The Settlement Agreement further provides that FT Global (together with its affiliates and attribution parties) may not exercise the Rights to the extent such exercise would result in its beneficial ownership of more than 9.99% of our outstanding common stock.

On June 24, 2025, the United States District Court for the Southern District of New York entered an Order Approving Issuance (the "Section 3(a)(10) Order") pursuant to Section 3(a)(10) of the Securities Act, in the matter of FT Global Capital, Inc. v. Future FinTech Group Inc., Case No. 1:24-mc-00257-AKH. The Section 3(a)(10) Order ordered that the issuance and/or transfer of Rights Shares to FT Global or its designees(s), pursuant to the Settlement Agreement, was approved as fair within the meaning of Section 3(a)(10) of the Securities Act, and the Rights Shares are exempt from registration with the SEC and shall be issued without any restrictive legends.

Notwithstanding, since FT Global, a registered broker-dealer, may be deemed to be an 'underwriter' within the meaning of Section 2(a)(11) of the Securities Act in connection with the resale of the common stock, we are registering all of the Rights Shares for an aggregate of 2,600,000 shares of common stock (including a potential 1,300,000 shares of common stock, to the extent that the Company will be required to true-up the shares due to FT Global).

Anti-Takeover Effects of Certain Provisions of Florida Law

As a Florida corporation, we are also subject to certain provisions of the FCBA that have anti-takeover effects and may inhibit a non-negotiated merger or other business combination. Our Articles of Incorporation and Bylaws also contain other provisions which could have anti-takeover effects. These provisions include, without limitation, the authority of our Board of Directors to issue additional shares of preferred stock and to fix the relative rights and preferences of the preferred stock without the need for any shareholder vote or approval, as discussed above, and advance notice procedures to be complied with by our shareholders in order to make shareholder proposals or nominate directors.

In addition, the FBCA prohibits the voting of shares in an "issuing public corporation" that are acquired in a "control share acquisition" unless the board of directors of the corporation approves the control share acquisition before the acquisition or the holders of a majority of the corporation's voting shares (excluding shares held by officers of the corporation, inside directors of the corporation or the acquiring party) approve the granting of voting rights as to the shares acquired in the control share acquisition. An "issuing public corporation" is a corporation that has (i) 100 or more shareholders, (ii) its principal place of business, its principal office or substantial assets in Florida and (iii) either more than 10% of its shareholders residing in Florida, more than 10% of its shares owned by Florida residents or 1,000 shareholders residing in Florida "Control shares" are defined in the FBCA as shares acquired by a person, either directly or indirectly, that when added to all other shares of the issuing corporation owned by that person, would entitle that person to exercise, either directly or indirectly, voting power in the election of directors within any of the following ranges: (i) 20% or more but less than 33% of all voting power of the corporation's voting securities; (ii) 33% or more but less than a majority of all voting power of the corporation's voting securities; or (iii) a majority or more of all of the voting power of the corporation's voting securities. These provisions do not apply to shares acquired under, among other things, an agreement or plan of merger or share exchange effected in compliance with the relevant provisions of the FBCA and to which the corporation is a party, or an acquisition of shares previously approved by the board of directors of the corporation.

Transfer Agent

The transfer agent and registrar for our common stock is Transhare Corporation. The transfer agent and registrar's address is Bayside Center 1, 17755 US Highway 19 N, Suite 140, Clearwater, Florida 33764 and its telephone number is (303) 662-1112.

SELLING STOCKHOLDERS

The Selling Stockholders may from time to time offer and sell any or all of the securities set forth below pursuant to this prospectus and any accompanying prospectus supplement. As used in this prospectus, the term "Selling Stockholders" includes the persons listed in the table below, together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the selling stockholders' interests in the securities, other than through a public sale. Except for the ownership of the securities of the Company or as set forth below, the Selling Stockholders have not had any material relationship with us within the past three years.

Except as set forth in the footnotes below, the following table sets forth certain information as of September 30, 2025 regarding the beneficial ownership of the securities by the Selling Stockholders and the securities being offered by the Selling Stockholders. The applicable percentage ownership of the common stock is based on 20,153,311 shares outstanding as of September 30, 2025. The Selling Stockholders may offer and sell some, all or none of securities.

Beneficial ownership is determined in accordance with the rules and regulations of the SEC. A person is a "beneficial owner" of a security if that person has or shares "voting power," which includes the power to vote or to direct the voting of the security, or "investment power," which includes the power to dispose of or to direct the disposition of the security, or has the right to acquire such powers within 60 days.

Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned securities.

Selling Stockholders		Beneficial Ownership Before the Offering(1)				Percentage of Ownership Before the Offering (3)				Number of Shares Being Offered (2)				Percentage of Ownership After the Offering (3)(14)
Avondale Capital, LLC(5)			1,505,000	(4)			7.47	%(4)			11,505,000	(4)			-
FT Global Capital, Inc.(6)			247,000-	(7)			1.23	%			2,600,000	(7)			-
Lyu Jiajia (8)			1,000,000				4.96	%			1,000,000				-
Huang Tianyi (9)			1,000,000				4.96	%			1,000,000				-
Zhan Jiarui (10)			1,000,000				4.96	%			1,000,000				-
Chen Yanfen (11)			1,000,000				4.96	%			1,000,000				-
Liu Xiqiao (12)			1,000,000				4.96	%			1,000,000				-
Lia Jianpeng (13)			1,000,000				4.96	%			1,000,000				-

(1)

Represents the total number of shares of our common stock beneficially owned by the Selling Stockholders as of the date of this prospectus, without regard to ownership limitations described in footnote (2) below.

(2)

Assumes that all 10,000,000 shares being registered pursuant to the Pre-Paid SPA were issued to Avondale. The Pre-Paid SPA contains a beneficial ownership limitation, which provides that Avondale will not have the right to purchase shares of our common stock if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such purchase. Also assumes that FT Global exercises its Series A Right of 650,000 shares and Series B Right of 650,000 shares. In addition, this assumes that the closing bid price of the Company is less than $1.00 at the time of FT Global's exercise, and thus we are registering an additional 1,300,000 shares of common stock, to the extent that the Company will be required to true-up the shares due to FT Global or its designee, pursuant to the Settlement Agreement. The Settlement Agreement also contains a 9.99% beneficial ownership limitation. Except as specifically noted in the footnotes below, the shares set forth in the table do not reflect the foregoing ownership limitations.

(3)

Percentages are based on 20,153,311 shares of common stock outstanding as of September 30, 2025.

(4)

The shares of common stock set forth in the column "Beneficial Ownership Before the Offering" consists of the 60,000 Commitment Shares and 1,445,000 Pre-Delivery Shares beneficially owned by Avondale issued pursuant to the Pre-Paid SPA. The shares of common stock set forth in the column "Number of Shares Being Offered" consists of the 60,000 Commitment Shares, 1,445,000 Pre-Delivery Shares and up to 10,000,000 shares of common stock that Avondale can purchase pursuant to the Pre-Paid SPA. The number of shares of common stock that may actually be acquired by Avondale pursuant to the Pre-Paid SPA is not currently known and is subject to satisfaction of certain conditions and limitations, including the limitation that we shall not effect the issuance of common stock that would cause Avondale to beneficially own a number of shares of common stock exceeding 9.99% of the number of shares of common stock outstanding on such date, as set forth in the Pre-Paid SPA.

(5)

John M. Fife has voting and dispositive power over securities held by Avondale. The business address of Avondale is 297 Auto Mall Drive #4, St. George, Utah 84770.

(6)

Jian Ke is President, Chief Executive Officer and the sole director of FT Global Capital Inc.("FT Global") and may be deemed to have voting and dispositive power over the shares beneficially owned by FT Global. The business address of FT Global Capital Inc. is 1688 Meridian Avenue, Suite 700, Miami Beach, Florida 33139.

(7)

The shares of common stock set forth in the column "Number of Shares Being Offered" include: (i) 650,000 shares of common stock issuable to Jian Ke, FT Global's designee, upon the exercise of its Series A Right; (ii) 650,000 shares of common stock issuable to Jian Ke, FT Global's designee upon the exercise of its Series B Right; and (iii) 1,300,000 shares of common stock, to the extent that the Company will be required to true-up the shares due to FT Global or its designee, Jian Ke, pursuant to the Settlement Agreement. Such ownership of the Company's common stock is subject to the 9.99% beneficial ownership limitation set forth in the Settlement Agreement.

(8)

Lyu Jiajia's address is No. 11 Min An Road San Xiang ,Shuang Guo Ju Wei Hui Huai Cheng Town, Huai Ji County, Guang Dong, China.

(9)

Huang Tianyi's address is Room 1602, Building 1, Sanhe Garden, Lane123 Yanping Road, Jing An District, Shanghai, China.

(10)

Zhan Jiarui's address is No. 2-353 Di Xing Ju, Dong Cheng District, Beijing, China.

(11)

Chen Yanfen's address is No. 34-201 Liu Jia Yao Nan Li, Liu Jia Yao Road, Feng TaiDistrict, Beijing, China.

(12)

Liu Xiqiao's address is No. 7-2-502 Ren Hong Jia Yuan, Ma Ju Qiao, Tong Zhou District, Beijing, China

(13)

Lia Jianpeng's address is c/o No. 6-1-902 Xi Si Lai Gong Guan, Gao Mi Dian Nan, Da Xing District, Beijing, China.

(14)

Assumes the sale of all shares offered herein.

PLAN OF DISTRIBUTION

The Selling Stockholders, and each of them, will pay all incremental selling expenses relating to the sale of their shares of common stock, including underwriters' commissions and discounts, brokerage fees, underwriter marketing costs and all reasonable fees and expenses of any legal counsel representing the Selling Stockholders, as applicable. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares of common stock covered by this prospectus, including, without limitation, all registration and filing fees, printing and delivery fees, Nasdaq Stock Market listing fees and fees and expenses of our counsel and our accountants.

The shares of common stock beneficially owned by the Selling Stockholders covered by this prospectus may be offered and sold from time to time by the Selling Stockholders. The term "Selling Stockholders" includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from the Selling Stockholders as a gift, pledge, partnership distribution or other transfer. The Selling Stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the then-current market price or in negotiated transactions. The Selling Stockholders may sell their shares of common stock by one or more of, or a combination of, the following methods:

●

purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus;

●

ordinary brokerage transactions and transactions in which the broker solicits purchasers;

●

block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

●

an over-the-counter distribution in accordance with the rules of the Nasdaq Stock Market;

●

through trading plans entered into by the Selling Stockholders pursuant to Rule 10b5-1 under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans;

●

to or through underwriters or broker-dealers;

●

in "at the market" offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents;

●

in privately negotiated transactions;

●

in options transactions;

●

through a combination of any of the above methods of sale; or

●

any other method permitted pursuant to applicable law.

The Selling Stockholders may also sell securities under Rule 144 under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by a Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

In connection with the sale of the securities covered hereby, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholders are "underwriters" within the meaning of Section 2(a)(11) of the Securities Act. Any broker-dealers or agents that may become involved in selling the registered shares offered under this prospectus may be deemed to be "underwriters" within the meaning of the Securities Act in connection with these sales. Any broker-dealers or agents that are deemed to be underwriters may not sell registered shares offered under this prospectus unless and until we set forth the names of the underwriters and the material details of their underwriting arrangements in a replacement prospectus included in a post-effective amendment to the registration statement of which this prospectus is a part.

If any of the Selling Stockholders are deemed to be "underwriters" within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act, including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. We are requesting that the Selling Stockholders confirm that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale securities by the Selling Stockholders.

We intend to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for us to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

Avondale has agreed that, during the term of the Pre-Paid SPA, it will not engage in any short sales with respect to our common stock; provided that the sale of common stock received by Avondale after delivery of a Purchase Notice, but prior to the receipt of the Purchase Shares, is not deemed a short sale under Regulation SHO. In addition, so long as no event of default has occurred under the Pre-Paid SPA, Avondale has agreed that it will not sell, during any calendar week, shares of our common stock acquired under the Pre-Paid SPA in an amount exceeding 15% of the total weekly trading volume of our common stock on all trading markets during such week. We have agreed in the Pre-Paid SPA to provide customary indemnification to Avondale.

The Selling Stockholders and any unaffiliated broker-dealer that is deemed to be an underwriter will be subject to liability under the federal securities laws and must comply with the requirements of the Exchange Act, including without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of sales of our common stock by the Selling Stockholders or any unaffiliated broker-dealer. Under these rules and regulations, the Selling Stockholders and any unaffiliated broker-dealer:

●

may not engage in any stabilization activity in connection with our securities;

●

must furnish each broker which offers shares of our common stock covered by the prospectus and accompanying prospectus that are a part of our registration statement with the number of copies of such prospectus and accompanying prospectus which are required by each broker; and

●

may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.

These restrictions may affect the marketability of our common stock by the Selling Stockholders and any unaffiliated broker-dealer.

We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our common stock covered by this prospectus by the Selling Stockholders.

We have advised the Selling Stockholders that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Stockholders, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.

This offering will terminate on the date that all shares of our common stock offered by this prospectus have been sold by the Selling Stockholders.

Under the Registration Rights Agreement, we have agreed to indemnify Avondale against certain liabilities that it may incur in connection with the sale of the securities pursuant to this prospectus, including liabilities under the Securities Act, and to contribute to payments that Avondale may be required to make with respect thereto. In addition, we and Avondale may agree to indemnify any underwriter, broker-dealer or agent against certain liabilities related to the selling of the securities, including liabilities arising under the Securities Act.

MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

The following is a discussion of the material U.S. federal income tax considerations generally applicable to the acquisition, ownership and disposition of our common stock. This discussion is limited to certain U.S. federal income tax considerations to beneficial owners of our securities who hold the securities as a capital asset within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended (the "Code"). This discussion does not describe all of the tax consequences that may be relevant to you in light of your particular circumstances, including the alternative minimum tax, the Medicare contribution tax on certain investment income and the different consequences that may apply if you are subject to special rules that apply to certain types of investors, such as:

●

financial institutions or financial services entities;

●

broker-dealers;

●

insurance companies;

●

governments or agencies or instrumentalities thereof;

●

regulated investment companies;

●

real estate investment trusts;

●

expatriates or former long-term residents of the United States;

●

persons that actually or constructively own five percent or more of our voting shares;

●

persons that acquired our securities pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation;

●

dealers or traders subject to a mark to market method of accounting with respect to the securities;

●

persons holding the securities as part of a "straddle," hedge, constructive sale, conversion or other integrated or similar transaction;

●

U.S. holders (as defined below) whose functional currency is not the U.S. dollar;

●

partnerships or other pass through entities for U.S. federal income tax purposes; and

●

tax exempt entities.

If you are a partnership for U.S. federal income tax purposes, the U.S. federal income tax treatment of your partners will generally depend on the status of the partners and your activities.

This discussion is based on the Code and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations as of the date hereof, changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state, local or non-U.S. taxation, or any U.S. tax law other than the U.S. federal income tax (such as gift, estate or Medicare contribution taxes) or except as discussed below, any tax reporting obligations of a holder of our securities. This discussion also assumes that any distribution made (or deemed made on our securities and any consideration received (or deemed received) by a holder from the sale or other disposition of our securities will be in U.S. dollars.

We have not sought, and will not seek, a ruling from the Internal Revenue Service (the "IRS") as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion.

THIS DISCUSSION IS ONLY A SUMMARY OF THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES. EACH PROSPECTIVE INVESTOR IN OUR SECURITIES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, AND NON-U.S. TAX LAWS, AS WELL AS U.S. FEDERAL TAX LAWS AND ANY APPLICABLE TAX TREATIES.

Personal Holding Company Status

We could be subject to a second level of U.S. federal income tax on a portion of our income if we are determined to be a personal holding company, or PHC, for U.S. federal income tax purposes. A U.S. corporation generally will be classified as a PHC for U.S. federal income tax purposes in a given taxable year if (i) at any time during the last half of such taxable year, five or fewer individuals (without regard to their citizenship or residency and including as individuals for this purpose certain entities such as certain tax-exempt organizations, pension funds and charitable trusts) own or are deemed to own (pursuant to certain constructive ownership rules) more than 50% of the stock of the corporation by value and (ii) at least 60% of the corporation's adjusted ordinary gross income, as determined for U.S. federal income tax purposes, for such taxable year consists of PHC income (which includes, among other things, dividends, interest, certain royalties, annuities and, under certain circumstances, rents).

Depending on the date and size of our transactions, at least 60% of our adjusted ordinary gross income may consist of PHC income as discussed above. In addition, depending on the concentration of our stock in the hands of individuals, including the members of our sponsor and certain tax-exempt organizations, pension funds and charitable trusts, more than 50% of our stock may be owned or deemed owned (pursuant to the constructive ownership rules) by such persons during the last half of a taxable year. Thus, no assurance can be given that we will not become a PHC following this offering or in the future. If we are or were to become a PHC in a given taxable year, we would be subject to an additional PHC tax, currently 20%, on our undistributed PHC income, which generally includes our taxable income, subject to certain adjustments. The PHC requirements may apply to us in the taxable year of the offering and/or future taxable years.

U.S. Holders

This section applies to you if you are a "U.S. holder." A U.S. holder is a beneficial owner of our securities who or that is, for U.S. federal income tax purposes:

●

an individual who is a citizen or resident of the United States;

●

a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) organized in or under the laws of the United States, any state thereof or the District of Columbia;

●

an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or

●

a trust if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii) it has in effect a valid election to be treated as a U.S. person.

Taxation of Distributions. If we pay cash distributions to U.S. holders of shares of our common stock, such distributions generally will be treated as a dividend for U.S. federal income tax purposes to the extent the distribution is paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. holder's adjusted tax basis in our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described under "U.S. holders - Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Our Securities" below.

Dividends we pay to a U.S. holder that is a taxable corporation generally will qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a non-corporate U.S. holder generally will constitute "qualified dividends" that will be subject to tax at the maximum tax rate accorded to long-term capital gains.

Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Our Securities. Upon a sale or other taxable disposition of our securities which, in general, would include a redemption of common, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. holder's adjusted tax basis in such securities. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. holder's holding period for the securities so disposed of exceeds one year. Long-term capital gains recognized by non-corporate U.S. holders will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to various limitations that are not described herein because a discussion of such limitations depends on each U.S. holder's particular facts and circumstances.

Generally, the amount of gain or loss recognized by a U.S. holder is an amount equal to the difference between (i) the sum of the amount of cash and the fair market value of any property received in such disposition and (ii) the U.S. holder's adjusted tax basis in its securities so disposed of. A U.S. holder's adjusted tax basis in its common stock generally will equal the U.S. holder's acquisition cost less, in the case of a share of common stock, any prior distributions treated as a return of capital.

Information Reporting and Backup Withholding. In general, information reporting requirements may apply to dividends paid to a U.S. holder and to the proceeds of the sale or other disposition of our securities, unless the U.S. holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. holder fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn).

Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a U.S. holder's U.S. federal income tax liability provided the required information is timely furnished to the IRS.

Non-U.S. Holders

This section applies to you if you are a "Non-U.S. holder." A Non-U.S. holder is a beneficial owner of our securities who or that is, for U.S. federal income tax purposes:

●

a non resident alien individual, other than certain former citizens and residents of the United States subject to U.S. tax as expatriates;

●

a foreign corporation; or

●

an estate or trust that is not a U.S. holder;

but does not include an individual who is present in the United States for 183 days or more in the taxable year of disposition. If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the sale or other disposition of a security.

Taxation of Distributions. In general, any distributions we make to a Non-U.S. holder of shares of our common stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the Non-U.S. holder's conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such Non-U.S. holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form W-8BEN or W-8BEN-E). Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S. holder's adjusted tax basis in its shares of our common stock and, to the extent such distribution exceeds the Non-U.S. holder's adjusted tax basis, as gain realized from the sale or other disposition of the common stock, which will be treated as described under "Non-U.S. holders - Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Securities" below. In addition, if we determine that we are classified as a "United States real property holding corporation" (see "Non-U.S. holders - Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Securities" below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits.

The withholding tax does not apply to dividends paid to a Non-U.S. holder who provides a Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. holder's conduct of a trade or business within the United States. Instead, the effectively connected dividends will be subject to regular U.S. federal income tax as if the Non-U.S. holder were a U.S. resident, subject to an applicable income tax treaty providing otherwise. A Non-U.S. corporation receiving effectively connected dividends may also be subject to an additional "branch profits tax" imposed at a rate of 30% (or a lower treaty rate).

Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Securities. A Non-U.S. holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our securities unless:

●

the gain is effectively connected with the conduct of a trade or business by the Non-U.S. holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. holder); or

●

we are or have been a "U.S. real property holding corporation" for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. holder held our securities, and, in the case where shares of our common stock are regularly traded on an established securities market, the Non-U.S. holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. holder's holding period for the shares of our common stock. There can be no assurance that our common stock will be treated as regularly traded on an established securities market for this purpose.

Unless an applicable treaty provides otherwise, gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the Non-U.S. holder were a U.S. resident. Any gains described in the first bullet point above of a Non-U.S. holder that is a foreign corporation may also be subject to an additional "branch profits tax" at a 30% rate (or lower treaty rate).

If the second bullet point above applies to a Non-U.S. holder, gain recognized by such holder on the sale, exchange or other disposition of our securities will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our securities from such holder may be required to withhold U.S. federal income tax at a rate of 15% of the amount realized upon such disposition. We will be classified as a U.S. real property holding corporation if the fair market value of our "U.S. real property interests" equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes.

Information Reporting and Backup Withholding. Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our securities. A Non-U.S. holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty will satisfy the certification requirements necessary to avoid the backup withholding as well. The amount of any backup withholding from a payment to a Non-U.S. holder will be allowed as a credit against such holder's U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.

FATCA Withholding Taxes. Provisions commonly referred to as "FATCA" impose withholding of 30% on payments of dividends (including constructive dividends) on our securities, and, beginning January 1, 2019, sales or other disposition proceeds from our securities to "foreign financial institutions" (which is broadly defined for this purpose and in general includes investment vehicles) and certain other Non-U.S. entities unless various U.S. information reporting and due diligence requirements (generally relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied, or an exemption applies (typically certified as to by the delivery of a properly completed IRS Form W-8BEN-E). If FATCA withholding is imposed, a beneficial owner of the payment that is not a foreign financial institution (or that is a foreign financial institution entitled to a reduced rate of withholding tax with respect to such payment under an income tax treaty) generally may be entitled to a refund or credit of any amounts withheld by filing a U.S. federal income tax return and providing certain other information to the IRS (which may entail significant administrative burden). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Prospective investors should consult their tax advisers regarding the effects of FATCA on their investment in our securities.

LEGAL MATTERS

The validity of the securities offered by this prospectus will be passed upon for us by Anthony, Linder & Cacomanolis, PLLC, West Palm Beach, Florida.

EXPERTS

The consolidated financial statements of Future Fintech Group Inc. incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2024 have been so incorporated in reliance on the report of Fortune CPA, Inc., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC the registration statement on Form S-1 under the Securities Act for the securities offered by this prospectus. This prospectus, which is a part of the registration statement, does not contain all of the information in the registration statement and the exhibits filed with it, portions of which have been omitted as permitted by SEC rules and regulations. For further information concerning us and the securities offered by this prospectus, we refer to the registration statement and to the exhibits filed with it. Statements contained in this prospectus as to the content of any contract or other document referred to are not necessarily complete. In each instance, we refer you to the copy of the contracts and/or other documents filed as exhibits to the registration statement.

We are subject to the reporting requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC's website at http://www.sec.gov. We also maintain a website at www.ftft.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.

INFORMATION INCORPORATED BY REFERENCE

The SEC allows us to "incorporate by reference" information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We filed a registration statement on Form S-1 under the Securities Act with the SEC with respect to the securities being offered pursuant to this prospectus. This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities being offered pursuant to this prospectus. Statements in this prospectus regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the registration statement, including the documents incorporated by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed above in "Where You Can Find More Information". We are incorporating by reference the documents listed below, which we have already filed with the SEC, and all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any future report or document that is not deemed filed under such provisions:

●

our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on April 15, 2025;

●

our Quarterly Reports on Form 10-Q for the period ended March 31, 2025 and June 30, 2025, filed with the SEC on May 20, 2025 and August 19, 2025, respectively;

●

our Current Reports on Form 8-K filed with the SEC on February 18, 2025, March 6, 2025, April 1, 2025, April 29, 2025, May 6, 2025, June 16, 2025, June 20, 2025, June 26, 2025, July 31, 2025, August 26, 2025, September 5, 2025, September 22, 2025, and September 26, 2025 and our Amended Current Report on Form 8-K/A filed with the SEC on April 2, 2025;

●

the description of our common stock which is included in Exhibit 4.3 of our Form 10-K filed with the SEC on April 15, 2025, including any amendment or report filed for the purpose of updating that description; and

●

all documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and before we stop offering the securities covered by this prospectus and any accompanying prospectus supplement.

Notwithstanding the foregoing, information and documents that we elect to furnish, but not file, or have furnished, but not filed, with the SEC in accordance with SEC rules and regulations is not incorporated into this prospectus and does not constitute a part hereof.

We also incorporate by reference all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are subsequently filed by us with the Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of the offering of the securities made by this prospectus (including documents filed after the date of the initial Registration Statement of which this prospectus is a part and prior to the effectiveness of the Registration Statement). These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.

Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement.

You may request, and we will provide you with, a copy of these filings, at no cost, by calling us at 888-622-1218 or by writing to us at the following address:

Future FinTech Group Inc.

02B-03A, 23/F, Sino Plaza, 255-257

Gloucester Road, Causeway Bay, Hong Kong

888-622-1218

Future FinTech Group Inc.

Resale of up to 20,105,000 Shares of Common Stock

By the Selling Stockholders

PROSPECTUS

Prospectus dated [___], 2025

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

Set forth below is an estimate (except in the case of the SEC registration fee) of the amount of fees and expenses to be incurred in connection with the securities registered hereby. All such amounts will be borne by Future FinTech Group Inc., a Florida corporation.

Type		Amount
SEC registration fee		$	6,756.38
Accounting fees and expenses		$	10,000.00
Legal fees and expenses		$	50,000.00
Transfer agent's fees and expenses		$	1,000.00
Miscellaneous fees and expenses		$	1,000.00
Total expenses		$	68,756.38

Item 14. Indemnification of Directors and Officers.

Florida law permits, under certain circumstances, the indemnification of any person with respect to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, to which such person was or is a party or is threatened to be made a party, by reason of them being an officer, director, employee or agent of the corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against liability incurred in connection with such proceeding, including appeals thereof; provided, however, that the officer, director, employee or agent acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. The termination of any such third-party action by judgment, order, settlement, or conviction or upon a plea of nolo contendere or its equivalent does not, of itself, create a presumption that the person (i) did not act in good faith and in a manner which he or she reasonably believed to be in, or not opposed to, the best interests of the corporation or (ii) with respect to any criminal action or proceeding, had reasonable cause to believe that their conduct was unlawful. In the case of proceedings by or in the right of the corporation, Florida law permits indemnification of any person by reason of the fact that such person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against liability incurred in connection with such proceeding, including appeals thereof; provided, however, that the officer, director, employee or agent acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification is made where such person is adjudged liable, unless a court of competent jurisdiction determines that, despite the adjudication of liability but in view of all circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

To the extent that such person is successful on the merits or otherwise in defending against any such proceeding, Florida law provides that they shall be indemnified against expenses actually and reasonably incurred by him or her in connection therewith.

Also, under Florida law, expenses incurred by an officer or director in defending a civil or criminal proceeding may be paid by the corporation in advance of the final disposition of such proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if he or she is ultimately found not to be entitled to indemnification by the corporation pursuant to the applicable section. Expenses incurred by other employees and agents may be paid in advance upon such terms or conditions that the Board of Directors deems appropriate.

Article VIII of our Articles of Incorporation, as amended, authorizes us, among other things, to indemnify our officers, directors, employees or agents against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by them in connection with certain actions, suits or proceedings if they acted in good faith and in a manner in which they reasonably believed to be in or not opposed to our best interests and, with respect to any criminal action or proceeding, have no reasonable cause to believe their conduct was unlawful. Article VII of our Bylaws authorizes us to indemnify our officers and directors to the fullest extent authorized or permitted by the FBCA. Our Bylaws provide that we will indemnify our directors and officers from liabilities incurred by them in connection with actions, suits or proceedings in which they are involved by reason of their acting as our directors and officers.

In addition to the authority granted to us by Florida law to indemnify our directors, certain other provisions of the FBCA have the effect of further limiting the personal liability of our directors. Pursuant to Florida law, a director of a Florida corporation cannot be held personally liable for monetary damages to the corporation or any other person for any act or failure to act regarding corporate management or policy except in the case of certain qualifying breaches of the director's duties.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

Item 15. Recent Sales of Unregistered Securities

In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.

On December 27, 2023, we entered into a Securities Purchase Agreement with Streeterville Capital, LLC, a Utah limited liability company, pursuant to which we sold and issued to the purchaser a Convertible Promissory Note (the "Note") in the principal amount of $1,100,000. The Purchaser purchased the Note with an original issue discount of $80,000, and we agreed to pay to the Purchaser $20,000 for fees and costs incurred by Purchaser in connection with the agreement.

On January 5, 2024, we entered into a Securities Purchase Agreement with certain purchasers, pursuant to which we agreed to sell to such in a private placement 2,150,536 shares (the "Shares") of common stock, at a purchase price of $1.20 per share for an aggregate price of $2,580,644. The private placement transaction was completed pursuant to the exemption from registration provided by Regulation S promulgated under the Securities Act of 1933, as amended.

On January 7, 2025, the holder of outstanding convertible note of the Company ("Note") elected to redeem a portion of the Note in 428,816 shares of common stock for an amount of $100,000 with a price of $0.2332 per share. On January 24, 2025, the same holder elected to redeem a portion of the Note in 183,230 shares of common stock for an amount $40,658 at a price of $0.2219 per share. The share numbers and prices are pre- reverse split effected on April 1, 2025.

On June 24, 2025, the United States District Court for the Southern District of New York entered an Order Approving Issuance (the "Section 3(a)(10) Order") pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended (the "Securities Act"), in the matter of FT Global Capital, Inc. v. Future FinTech Group Inc., Case No. 1:24-mc-00257-AKH. The Section 3(a)(10) Order ordered that the issuance and/or transfer of Settlement Shares (as defined below) to FT Global or its designees(s), pursuant to the Settlement Agreement, was approved as fair within the meaning of Section 3(a)(10) of the Securities Act, and the Settlement Shares are exempt from registration with the SEC and shall be issued without any restrictive legends. The Settlement Shares are as follows: (i) 340,000 shares of the Company's common stock to FT Global; (ii) 60,000 shares of the Company's common stock to Olshan Frome Wolosky LLP; (iii) 650,000 shares of the Company's common stock underlying a "Series A Right" for FT Global or its designees(s) to receive 650,000 shares of common stock, exercisable no earlier than six months after June 17, 2025; and (iv) 650,000 shares of common stock underlying a "Series B Right" for FT Global or its designees(s) to receive 650,000 shares of common stock, exercisable no earlier than 12 months after June 17, 2025.

On July 24, 2025, we entered into a securities purchase agreement (the "Equity SPA") with certain institutional and individual investors, pursuant to which we agreed to issue and sell, and the Purchasers agreed to purchase, up to an aggregate of 15,000,000 shares of common stock at a purchase price of $2.00 per share. The initial closing was capped at no more than 19.9% of our outstanding Common Stock as of the closing date and with the issuance of the remaining shares of Common Stock pursuant to the Equity SPA subject to shareholder approval, which was approved at a special meeting of stockholders on September 2, 2025.

On July 28, 2025, we entered into a Pre-Paid Securities Purchase Agreement (the "Pre-Paid SPA") with Avondale Capital, LLC, a Utah limited liability company ("Avondale") up to $10,000,000 worth of shares of common stock. On September 16, 2025, we issued 60,000 shares as Commitment Shares to Avondale as a fee pursuant to the Pre-Paid SPA. On September 24, 2025, we issued 1,445,000 Pre-Delivery Shares to Avondale in connection with the Pre-Paid SPA.

Unless otherwise noted, the foregoing shares were issued to an accredited investor without registration under the Securities Act of 1933, as amended (the "Securities Act"), based upon exemptions from registration provided under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The issuances did not involve any public offering.

Item 16. Exhibits.

The following documents are filed as exhibits to this registration statement:

EXHIBIT INDEX

Exhibit Number		Description
3.1		Third Amended and Restated Articles of Incorporation dated September 8, 2025. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Commission on September 5, 2025.
3.2		Amended and Restated Bylaws, dated August 6, 2025. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Commission on August 26, 2025.
4.1		Form of Placement Agent Warrant. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed with the Commission on December 28, 2020.
4.2		Description of Securities of the Registrant registered under Section 12 of the Securities Exchange Act of 1934, as amended. Incorporated by reference to Exhibit 4.3 to our Annual Report on Form 10-K filed with the Commission on April 15, 2025.
5.1*		Opinion of Anthony Linder & Cacomanolis PLLC
10.1		Form of Unrestricted Stock Award Agreement by and between Future FinTech Group Inc. and Grantees dated on July 12, 2022. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on July 15, 2022.
10.2		Share Transfer Agreement by and between Future FinTech (Hong Kong) Limited and Alpha Financial Limited dated February 27, 2023. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on March 1, 2023.
10.3		Form of Unrestricted Stock Award Agreement by and between Future FinTech Group Inc. and Grantees dated on December 23, 2023. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on December 26, 2023.
10.4		Securities Purchase Agreement by and between Future FinTech Group, Inc. and Streeterville Capital, LLC, dated December 27, 2023. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on December 27, 2023.
10.5		Convertible Promissory Note, issued by Future FinTech Group, Inc. to Streeterville Capital, LLC, dated December 27, 2023. Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Commission on December 27, 2023.
10.6		Form of Securities Purchase Agreement dated January 5, 2024. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on January 8, 2024.
10.7		Amendment to Convertible Promissory Note dated February 11, 2024. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on February 14, 2024.
10.8		Employment Agreement by and between Future FinTech Group, Inc. and Mr. Hu Li, dated August 5, 2024. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on August 9, 2024.
10.9		Director Agreement by and Between the Company and Mingyong Hu dated October 1, 2024. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on October 4, 2024.
10.10		Stock Purchase Agreement by and among Future FinTech Group Inc., FTFT SuperComputing Inc. and DDMM Capital LLC dated on December 6, 2024. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on December 11, 2024.

10.11		Settlement and Forbearance Agreement by and between Future FinTech Group Inc. and FT Global Capital, Inc. dated on June 17, 2025. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on June 20, 2025.
10.12		Order Approving Issuance pursuant to Section 3(a)(10) of the Securities Act of 1933 dated June 24, 2025. Incorporated by reference to Exhibit 99.1 to our Current Report on Form 8-K filed with the Commission on June 26, 2025.
10.13		Stipulation and Order dated June 24, 2025. Incorporated by reference to Exhibit 99.2 to our Current Report on Form 8-K filed with the Commission on June 26, 2025.
10.14		Form of Securities Purchase Agreements dated July 24, 2025. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on July 31, 2025.
10.15		Pre-Paid Securities Purchase Agreement by and between Future FinTech Group Inc. and Avondale Capital LLC dated July 28, 2025. Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Commission on July 31, 2025.
10.16		Pre-paid Purchase #1 Agreement by and between Future FinTech Group Inc. and Avondale Capital LLC dated July 28, 2025. Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the Commission on July 31, 2025.
10.17		Registration Rights Agreement by and between Future FinTech Group Inc. and Avondale Capital LLC dated July 28, 2025. Incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed with the Commission on July 31, 2025.
10.18		Pre-Paid Purchase #2 Agreement by and between Future FinTech Group Inc. and Avondale Capital LLC dated September 22, 2025. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Commission on September 26, 2025.
10.19		Waiver Letter from Avondale Capital LLC dated September 22, 2025. Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Commission on September 26, 2025.
14.1		Code of Business Conduct and Ethics Incorporated by reference to Exhibit 14.1 to our Annual Report on Form 10-K filed with the Commission on April 16, 2024.
19.1		Insider Trading Policy Incorporated by reference to Exhibit 19.1 to our Annual Report on Form 10-K filed with the Commission on April 16, 2024.
21.1*		Description of Subsidiaries of the Registrant
23.1*		Consent of Fortune CPA Inc.
23.2*		Consent of Anthony Linder & Cacomanolis PLLC (included in Exhibit 5.1)
24.1*		Power of Attorney (included on the signature page)
107*		Filing fee table
97.1		Clawback Policy Incorporated by reference to Exhibit 97.1 to our Annual Report on Form 10-K filed with the Commission on April 16, 2024.

*

Filed herewith

Item 17. Undertakings.

(a) The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 193, as amended (the "Securities Act");

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 ("Exchange Act") that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is a part of the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(5) That, for the purpose of determining liability under the Securities Act to any purchaser in the initial distribution of the securities, that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

(6) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communications that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Beijing, People's Republic of China, on September 30, 2025.

FUTURE FINTECH INC.
By:	/s/ Hu Li
	Hu Li
	Chief Executive Officer, President and Director (Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mr. Hu Li, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to sign any and all additional registration statements relating to the Registration Statement and filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent or his substitute or substitutes, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities held on September 30, 2025.

Name		Position
/s/ Hu Li		Chief Executive Officer, President and Director
Hu Li		(Principal Executive Officer)
/s/ Ting (Alina) Ouyang		Chief Financial Officer
Ting (Alina) Ouyang		(Principal Financial and Accounting Officer)
/s/ David Xu		Chairman of the Board
David Xu
/s/ Mingyoung Hu		Director
Mingyoung Hu
/s/ Mingjie Zhao		Director
Mingjie Zhao